Indeed, gemcitabine resistance is associated with EMT and induction of HIF-1α in pancreatic cancer cells (Wang et al. 2014), leading to the pharmacologic manipulation of HIF-1α as novel therapeutic approach to overcome resistance. The gene discussed is HIF1A; the disease is familial pancreatic carcinoma.